Ocuphire Pharma Investor Updates

P 9 Objectives and Key Eligibility Criteria VEGA-1 (OPI-NYXP-201) Phase 2 Trial Evaluating Nyxol + LDP for Treatment of Presbyopia Key Objectives PRIMARY To evaluate the efficacy of Nyxol + LDP to improve DCNVA compared to Placebo alone in presbyopia subjects ● KEY SECONDARY • To evaluate the ocular and systemic safety of Nyxol + LDP and each component individually • To evaluate multiple secondary visual acuity and pupil diameter endpoints Key Eligibility Criteria INCLUSION Males or females ≥ 40 and ≤ 64 years of age. BCDVA of 20/20 or better under photopic conditions • DCNVA of 20/50 or worse under photopic conditions Binocular best-corrected near VA is 20/25 or better EXCLUSION Clinically significant ocular disease Recent or current evidence of ocular infection or inflammation in either eye Clinical trial NCT#04675151. BCDVA is Best Corrected Distance Visual Acuity and DCNVA is Distance Corrected Near Visual Acuity Ocuphire PHARMA

View entire presentation